BBIO BridgeBio Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1743881 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY167.3%
TTM net income YoY29.0%
TTM EPS YoY28.0%
Revenue 3-yr CAGR364.6%
Net income 3-yr CAGR—
Margins
Gross margin94.3%
Operating margin-38.5%
Net margin-59.8%
FCF margin-39.1%
EBITDA margin-38.0%
Returns
ROE—
ROA-35.8%
ROIC (approx.)—
Asset turnover0.60x
Leverage & solvency
Liabilities / assets176.5%
Debt / equity—
Current ratio2.09x
Interest coverage-7.13x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $353.17M | $243.68M | $194.51M | $154.18M | $120.70M | $110.56M | $116.63M | $5.88M |
| Cost of revenue | $20.45M | $15.05M | $9.94M | $8.11M | $6.56M | $3.65M | $2.64M | $2.08M |
| Gross profit | $332.72M | $228.63M | $184.58M | $146.07M | $114.14M | $106.91M | $113.99M | $3.80M |
| R&D expense | $143.51M | $149.45M | $126.64M | $116.42M | $112.87M | $111.23M | $111.43M | $130.35M |
| SG&A expense | $200.85M | $186.26M | $163.90M | $158.09M | $137.62M | $129.15M | $106.36M | $94.78M |
| Operating income | -$11.64M | -$107.08M | -$105.96M | -$139.56M | -$145.20M | -$134.28M | -$104.37M | -$226.03M |
| Interest expense | $13.26M | $13.28M | $12.94M | $11.64M | $11.74M | $11.61M | $18.12M | $21.52M |
| Pretax income | -$59.27M | -$155.89M | — | -$194.75M | -$186.48M | -$181.66M | — | -$266.24M |
| Income tax | $1.23M | $0 | — | -$120,000 | -$1.54M | $2.10M | $0 | $1.15M |
| Net income | -$56.71M | -$152.22M | -$164.04M | -$192.86M | -$182.74M | -$181.90M | -$167.42M | -$265.05M |
| EBITDA | -$10.57M | -$106.03M | -$104.77M | -$138.13M | -$143.80M | -$132.96M | -$103.09M | -$224.66M |
| EPS (basic) | -0.42 | -0.78 | -0.84 | — | -0.95 | -0.95 | -0.88 | — |
| EPS (diluted) | -0.42 | -0.78 | -0.84 | — | -0.95 | -0.95 | -0.88 | — |
| Weighted avg. shares (diluted) | 196.03M | 195.79M | 194.79M | — | 191.85M | 190.52M | 190.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.53B | $677.91M | $879.89M | $570.12M | $642.95M | $748.95M | $540.60M | $681.10M |
| Short-term investments | $5.49M | $42.25M | $60.30M | $17.36M | $2.99M | $7.94M | — | $0 |
| Receivables | $375.09M | $254.48M | $205.23M | $139.44M | $116.52M | $76.87M | $115.27M | $4.72M |
| Inventory | $59.72M | $52.84M | $32.98M | $26.75M | $24.53M | $18.28M | $3.95M | $0 |
| Current assets | $2.04B | $1.09B | $1.24B | $797.75M | $839.38M | $912.28M | $695.17M | $720.69M |
| PP&E, net | $5.04M | $5.23M | $4.94M | $5.37M | $5.83M | $6.11M | $6.70M | $7.01M |
| Intangibles | $25.92M | $26.64M | $27.36M | $28.08M | $28.80M | $29.51M | $27.80M | $23.93M |
| Total assets | $2.16B | $1.22B | $1.37B | $936.02M | $998.25M | $1.08B | $881.64M | $919.34M |
| Current liabilities | $977.24M | $890.65M | $816.37M | $287.97M | $216.60M | $175.85M | $152.10M | $154.40M |
| Long-term debt | $2.63B | $2.65B | $2.65B | $2.01B | $2.01B | $0 | $0 | $437.34M |
| Total debt | $2.63B | $2.65B | $2.65B | $2.01B | $2.01B | $0 | $0 | $437.34M |
| Total liabilities | $3.82B | $3.72B | $3.64B | $3.01B | $2.92B | $2.86B | $2.52B | $2.38B |
| Shareholders' equity | -$1.66B | -$2.52B | -$2.28B | -$2.09B | -$1.93B | -$1.79B | -$1.65B | -$1.47B |
| Net debt | $1.10B | $1.97B | $1.77B | $1.44B | $1.36B | -$748.95M | -$540.60M | -$243.76M |
| Shares outstanding | 196.00M | 195.28M | 195.71M | 194.77M | 192.63M | 191.16M | 189.83M | 190.04M |
| Cash flow statement | ||||||||
| Operating cash flow | -$44.17M | -$71.10M | -$197.28M | -$56.42M | -$109.57M | -$80.68M | -$199.24M | -$195.33M |
| Capital expenditure | $290,000 | $443,000 | $69,000 | $33,000 | $470,000 | $594,000 | $0 | $47,000 |
| Free cash flow | -$44.46M | -$71.54M | -$197.35M | -$56.45M | -$110.04M | -$81.28M | -$199.24M | -$195.37M |
| Investing cash flow | $36.61M | $17.89M | -$42.73M | -$14.35M | $4.46M | -$13.00M | -$1.59M | -$3.24M |
| Financing cash flow | $863.01M | -$148.77M | $549.89M | -$2.18M | -$894,000 | $302.04M | $60.33M | $473.93M |
| Depreciation & amortization | $1.07M | $1.05M | $1.19M | $1.44M | $1.40M | $1.32M | $1.28M | $1.37M |
| Stock-based compensation | $39.86M | $44.52M | $33.24M | $34.64M | $35.26M | $37.34M | $25.88M | $30.13M |
| Share buybacks | $42.50M | $127.50M | $82.50M | $0 | $0 | $0 | $48.28M | $0 |
Free plan shows the latest 8 periods; Pro shows all 33 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.